{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:02:29Z","timestamp":1791230549285,"version":"4.1.0"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00415-022-11267-9","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T16:24:00Z","timestamp":1657729440000},"page":"5762-5786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-0334","authenticated-orcid":false,"given":"Chukwunonso K.","family":"Nwabufo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omozojie P.","family":"Aigbogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"11267_CR1","unstructured":"Parkinson\u2019s Foundation (2022) Statistics. https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Statistics"},{"key":"11267_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML de Lau","year":"2006","unstructured":"de Lau LML, Breteler MMB (2006) Epidemiology: Parkinson\u2019s disease. Lancet Neurol 5:525. https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9","journal-title":"Lancet Neurol"},{"key":"11267_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00441-004-0975-6","volume":"318","author":"T Klockgether","year":"2004","unstructured":"Klockgether T (2004) Parkinson\u2019s disease: clinical aspects. Cell Tissue Res 318:115\u2013120. https:\/\/doi.org\/10.1007\/s00441-004-0975-6","journal-title":"Cell Tissue Res"},{"key":"11267_CR4","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6895.1000298","author":"G Ayano","year":"2016","unstructured":"Ayano G (2016) Parkinson\u2019s disease: a concise overview of etiology, epidemiology, diagnosis, comorbidity and management. J Neurol Disord. https:\/\/doi.org\/10.4172\/2329-6895.1000298","journal-title":"J Neurol Disord"},{"key":"11267_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368\u2013376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11267_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","volume":"6","author":"JM Shulman","year":"2011","unstructured":"Shulman JM, De Jager PL, Feany MB (2011) Parkinson\u2019s disease: genetics and pathogenesis. Annu Rev Pathol 6:193\u2013222. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130242","journal-title":"Annu Rev Pathol"},{"key":"11267_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bpa.12370","volume":"26","author":"A Atik","year":"2016","unstructured":"Atik A, Stewart T, Zhang J (2016) Alpha-synuclein as a biomarker for Parkinson\u2019s disease. Brain Pathol 26:410\u2013418. https:\/\/doi.org\/10.1111\/bpa.12370","journal-title":"Brain Pathol"},{"key":"11267_CR8","unstructured":"Parkinson\u2019s UK (2022) https:\/\/www.parkinsons.org.uk\/news\/poll-finds-quarter-people-parkinsons-are-wrongly-diagnosed. Accessed 26 Jun 2022"},{"key":"11267_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/jnnp.73.5.529","volume":"73","author":"A Schrag","year":"2002","unstructured":"Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson\u2019s disease in the community? J Neurol Neurosurg Psychiatry 73:529\u2013534","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11267_CR10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom BR (2004) Parkinson\u2019s disease. Lancet 363:1783\u20131793. https:\/\/doi.org\/10.1016\/S0140-6736(04)16305-8","journal-title":"Lancet"},{"key":"11267_CR11","volume-title":"Epidemiology of movement disorders","author":"A Schrag","year":"2007","unstructured":"Schrag A (2007) Epidemiology of movement disorders. Lippincott Williams & Wilkins, Hagerstown"},{"key":"11267_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.00652","volume":"10","author":"N Limphaibool","year":"2019","unstructured":"Limphaibool N, Iwanowski P, Holstad MJV et al (2019) Infectious etiologies of Parkinsonism: pathomechanisms and clinical implications. Front Neurol 10:1\u201311. https:\/\/doi.org\/10.3389\/fneur.2019.00652","journal-title":"Front Neurol"},{"key":"11267_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/NRL.0b013e318251e6f2","volume":"18","author":"KS Zheng","year":"2012","unstructured":"Zheng KS, Dorfman BJ, Christos PJ et al (2012) Clinical characteristics of exacerbations in Parkinson disease. Neurologist 18:120\u2013124. https:\/\/doi.org\/10.1097\/NRL.0b013e318251e6f2","journal-title":"Neurologist"},{"key":"11267_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30305-7","author":"ME Cohen","year":"2020","unstructured":"Cohen ME, Eichel R, Steiner-Birmanns B et al (2020) A case of probable Parkinson\u2019s disease after SARS-CoV-2 infection. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(20)30305-7","journal-title":"Lancet Neurol"},{"key":"11267_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010282","author":"A M\u00e9ndez-Guerrero","year":"2020","unstructured":"M\u00e9ndez-Guerrero A, Laespada-Garc\u00eda MI, G\u00f3mez-Grande A et al (2020) Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000010282","journal-title":"Neurology"},{"key":"11267_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/mds.28277","volume":"35","author":"I Faber","year":"2020","unstructured":"Faber I, Brand\u00e3o PRP, Menegatti F et al (2020) Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov Disord 35:1721\u20131722. https:\/\/doi.org\/10.1002\/mds.28277","journal-title":"Mov Disord"},{"key":"11267_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117331","volume":"422","author":"K Makhoul","year":"2021","unstructured":"Makhoul K, Jankovic J (2021) Parkinson\u2019s disease after COVID-19. J Neurol Sci 422:117331. https:\/\/doi.org\/10.1016\/j.jns.2021.117331","journal-title":"J Neurol Sci"},{"key":"11267_CR18","doi-asserted-by":"publisher","first-page":"333.e1","DOI":"10.1016\/j.ajem.2021.02.050","volume":"47","author":"NB Akilli","year":"2021","unstructured":"Akilli NB, Yosunkaya A (2021) Part of the Covid19 puzzle: acute parkinsonism. Am J Emerg Med 47:333.e1-333.e3. https:\/\/doi.org\/10.1016\/j.ajem.2021.02.050","journal-title":"Am J Emerg Med"},{"key":"11267_CR19","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1007\/s00415-021-10560-3","volume":"268","author":"M Morassi","year":"2021","unstructured":"Morassi M, Palmerini F, Nici S et al (2021) SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol 268:3980\u20133987. https:\/\/doi.org\/10.1007\/s00415-021-10560-3","journal-title":"J Neurol"},{"key":"11267_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1101\/gr.8.9.871","volume":"8","author":"C Lavedan","year":"1998","unstructured":"Lavedan C (1998) The synuclein family. Genome Res 8:871\u2013880. https:\/\/doi.org\/10.1101\/gr.8.9.871","journal-title":"Genome Res"},{"key":"11267_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0304-3940(02)00154-4","volume":"323","author":"PJ McLean","year":"2002","unstructured":"McLean PJ, Hyman BT (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci Lett 323:219\u2013223","journal-title":"Neurosci Lett"},{"key":"11267_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jmb.2011.05.046","volume":"411","author":"K Levitan","year":"2011","unstructured":"Levitan K, Chereau D, Cohen SI et al (2011) Conserved C-terminal charge exerts a profound influence on the aggregation rate of alpha-synuclein. J Mol Biol 411:329\u2013333. https:\/\/doi.org\/10.1016\/j.jmb.2011.05.046","journal-title":"J Mol Biol"},{"key":"11267_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12035-012-8330-5","volume":"47","author":"K Beyer","year":"2013","unstructured":"Beyer K, Ariza A (2013) alpha-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol 47:509\u2013524. https:\/\/doi.org\/10.1007\/s12035-012-8330-5","journal-title":"Mol Neurobiol"},{"key":"11267_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","volume":"14","author":"A Iwai","year":"1995","unstructured":"Iwai A, Masliah E, Yoshimoto M et al (1995) The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467\u2013475","journal-title":"Neuron"},{"key":"11267_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0169-328X(94)90187-2","volume":"27","author":"S Nakajo","year":"1994","unstructured":"Nakajo S, Shioda S, Nakai Y, Nakaya K (1994) Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res Mol Brain Res 27:81\u201386","journal-title":"Brain Res Mol Brain Res"},{"key":"11267_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211","journal-title":"Neurobiol Aging"},{"key":"11267_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","volume":"287","author":"R Borghi","year":"2000","unstructured":"Borghi R, Marchese R, Negro A et al (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson\u2019s disease and normal subjects. Neurosci Lett 287:65\u201367","journal-title":"Neurosci Lett"},{"key":"11267_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","volume":"20","author":"OM El-Agnaf","year":"2006","unstructured":"El-Agnaf OM, Salem SA, Paleologou KE et al (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease. FASEB J 20:419\u2013425. https:\/\/doi.org\/10.1096\/fj.03-1449com","journal-title":"FASEB J"},{"key":"11267_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","volume":"113","author":"PH Lee","year":"2006","unstructured":"Lee PH, Lee G, Park HJ et al (2006) The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy. J Neural Transm (Vienna) 113:1435\u20131439. https:\/\/doi.org\/10.1007\/s00702-005-0427-9","journal-title":"J Neural Transm (Vienna)"},{"key":"11267_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230\u2013240. https:\/\/doi.org\/10.1016\/S1474-4422(11)70014-X","journal-title":"Lancet Neurol"},{"key":"11267_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda T, Salem SA, Allsop D et al (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease. Biochem Biophys Res Commun 349:162\u2013166. https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.024","journal-title":"Biochem Biophys Res Commun"},{"key":"11267_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1006\/jmbi.2001.4538","volume":"307","author":"D Eliezer","year":"2001","unstructured":"Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307:1061\u20131073. https:\/\/doi.org\/10.1006\/jmbi.2001.4538","journal-title":"J Mol Biol"},{"key":"11267_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nrm2204","volume":"8","author":"A Aguzzi","year":"2007","unstructured":"Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8:552\u2013561. https:\/\/doi.org\/10.1038\/nrm2204","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11267_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","volume":"148","author":"D Eisenberg","year":"2012","unstructured":"Eisenberg D, Jucker M (2012) The amyloid state of proteins in human diseases. Cell 148:1188\u20131203. https:\/\/doi.org\/10.1016\/j.cell.2012.02.022","journal-title":"Cell"},{"key":"11267_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1326-8-17","volume":"8","author":"AN Sacino","year":"2013","unstructured":"Sacino AN, Thomas MA, Ceballos-Diaz C et al (2013) Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener 8:17. https:\/\/doi.org\/10.1186\/1750-1326-8-17","journal-title":"Mol Neurodegener"},{"key":"11267_CR36","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1021\/acschemneuro.6b00209","volume":"7","author":"J Kakish","year":"2016","unstructured":"Kakish J, Allen KJ, Harkness TA et al (2016) Novel dimer compounds that bind alpha-synuclein can rescue cell growth in a yeast model overexpressing alpha-synuclein. A possible prevention strategy for Parkinson\u2019s disease. ACS Chem Neurosci 7:1671\u20131680. https:\/\/doi.org\/10.1021\/acschemneuro.6b00209","journal-title":"ACS Chem Neurosci"},{"key":"11267_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1474-4422(07)70302-2","volume":"7","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease and movement disorders: moving forward. Lancet Neurol 7:9\u201311. https:\/\/doi.org\/10.1016\/S1474-4422(07)70302-2","journal-title":"Lancet Neurol"},{"key":"11267_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","volume":"5","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson\u2019s disease. Lancet Neurol 5:75\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(05)70285-4","journal-title":"Lancet Neurol"},{"key":"11267_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson\u2019s disease. Annu Rev Neurosci 28:57\u201387. https:\/\/doi.org\/10.1146\/annurev.neuro.28.061604.135718","journal-title":"Annu Rev Neurosci"},{"key":"11267_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.parkreldis.2009.11.002","volume":"16","author":"AB Sollinger","year":"2010","unstructured":"Sollinger AB, Goldstein FC, Lah JJ et al (2010) Mild cognitive impairment in Parkinson\u2019s disease: subtypes and motor characteristics. Parkinsonism Relat Disord 16:177\u2013180. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.11.002","journal-title":"Parkinsonism Relat Disord"},{"key":"11267_CR41","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson\u2019s disease. Neurology 57:1497\u20131499","journal-title":"Neurology"},{"key":"11267_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.55.7.969","volume":"55","author":"I Litvan","year":"1998","unstructured":"Litvan I, MacIntyre A, Goetz CG et al (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55:969\u2013978","journal-title":"Arch Neurol"},{"key":"11267_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S0317167100031814","volume":"18","author":"AH Rajput","year":"1991","unstructured":"Rajput AH, Rozdilsky B, Rajput A (1991) Accuracy of clinical diagnosis in parkinsonism\u2014a prospective study. Can J Neurol Sci 18:275\u2013278","journal-title":"Can J Neurol Sci"},{"key":"11267_CR44","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","volume":"42","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson\u2019s disease: a clinicopathologic study. Neurology 42:1142\u20131146","journal-title":"Neurology"},{"key":"11267_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289:18\u201322. https:\/\/doi.org\/10.1016\/j.jns.2009.08.034","journal-title":"J Neurol Sci"},{"key":"11267_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord 20:1255\u20131263. https:\/\/doi.org\/10.1002\/mds.20527","journal-title":"Mov Disord"},{"key":"11267_CR47","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Hollmann M et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276:2045\u20132048. https:\/\/doi.org\/10.1126\/science.276.5321.2045","journal-title":"Science"},{"key":"11267_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1212\/01.wnl.0000271080.53272.c7","volume":"70","author":"TB Ahn","year":"2008","unstructured":"Ahn TB, Kim SY, Kim JY et al (2008) alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70:43\u201349. https:\/\/doi.org\/10.1212\/01.wnl.0000271080.53272.c7","journal-title":"Neurology"},{"key":"11267_CR49","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","volume":"62","author":"DW Miller","year":"2004","unstructured":"Miller DW, Hague SM, Clarimon J et al (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835\u20131838","journal-title":"Neurology"},{"key":"11267_CR50","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","volume":"25","author":"HJ Lee","year":"2005","unstructured":"Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25:6016\u20136024. https:\/\/doi.org\/10.1523\/JNEUROSCI.0692-05.2005","journal-title":"J Neurosci"},{"key":"11267_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.94","volume":"3","author":"O Marques","year":"2012","unstructured":"Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350. https:\/\/doi.org\/10.1038\/cddis.2012.94","journal-title":"Cell Death Dis"},{"key":"11267_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbrc.2007.04.108","volume":"358","author":"M Nakai","year":"2007","unstructured":"Nakai M, Fujita M, Waragai M et al (2007) Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson\u2019s disease, in erythropoietic lineage. Biochem Biophys Res Commun 358:104\u2013110. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.108","journal-title":"Biochem Biophys Res Commun"},{"key":"11267_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/WNL.52.6.1269","volume":"52","author":"K Iwanaga","year":"1999","unstructured":"Iwanaga K, Wakabayashi K, Yoshimoto M et al (1999) Lewy body-type degeneration in cardiac plexus in Parkinson\u2019s and incidental Lewy body diseases. Neurology 52:1269\u20131271","journal-title":"Neurology"},{"key":"11267_CR54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00401-008-0450-7","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, White CL 3rd, Hladik CL et al (2009) Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117:169\u2013174. https:\/\/doi.org\/10.1007\/s00401-008-0450-7","journal-title":"Acta Neuropathol"},{"key":"11267_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","volume":"396","author":"H Braak","year":"2006","unstructured":"Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner\u2019s and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology. Neurosci Lett 396:67\u201372. https:\/\/doi.org\/10.1016\/j.neulet.2005.11.012","journal-title":"Neurosci Lett"},{"key":"11267_CR56","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/gut.2008.162503","volume":"57","author":"T Lebouvier","year":"2008","unstructured":"Lebouvier T, Chaumette T, Damier P et al (2008) Pathological lesions in colonic biopsies during Parkinson\u2019s disease. Gut 57:1741\u20131743. https:\/\/doi.org\/10.1136\/gut.2008.162503","journal-title":"Gut"},{"key":"11267_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012728","volume":"5","author":"T Lebouvier","year":"2010","unstructured":"Lebouvier T, Neunlist M, Bruley des Varannes S et al (2010) Colonic biopsies to assess the neuropathology of Parkinson\u2019s disease and its relationship with symptoms. PLoS ONE 5:e12728. https:\/\/doi.org\/10.1371\/journal.pone.0012728","journal-title":"PLoS ONE"},{"key":"11267_CR58","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1111\/j.1365-2982.2012.01887.x","volume":"24","author":"H Pouclet","year":"2012","unstructured":"Pouclet H, Lebouvier T, Coron E et al (2012) A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson\u2019s disease. Neurogastroenterol Motil 24:e202\u2013e205. https:\/\/doi.org\/10.1111\/j.1365-2982.2012.01887.x","journal-title":"Neurogastroenterol Motil"},{"key":"11267_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.nbd.2011.08.014","volume":"45","author":"H Pouclet","year":"2012","unstructured":"Pouclet H, Lebouvier T, Coron E et al (2012) A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson\u2019s disease. Neurobiol Dis 45:305\u2013309. https:\/\/doi.org\/10.1016\/j.nbd.2011.08.014","journal-title":"Neurobiol Dis"},{"key":"11267_CR60","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.23838","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon KM, Keshavarzian A, Mutlu E et al (2012) Alpha-synuclein in colonic submucosa in early untreated Parkinson\u2019s disease. Mov Disord 27:709\u2013715. https:\/\/doi.org\/10.1002\/mds.23838","journal-title":"Mov Disord"},{"key":"11267_CR61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/brain\/awm302","volume":"131","author":"S Orimo","year":"2008","unstructured":"Orimo S, Uchihara T, Nakamura A et al (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain 131:642\u2013650. https:\/\/doi.org\/10.1093\/brain\/awm302","journal-title":"Brain"},{"key":"11267_CR62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.21989","volume":"23","author":"H Fujishiro","year":"2008","unstructured":"Fujishiro H, Frigerio R, Burnett M et al (2008) Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson\u2019s disease. Mov Disord 23:1085\u20131092. https:\/\/doi.org\/10.1002\/mds.21989","journal-title":"Mov Disord"},{"key":"11267_CR63","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-009-0596-y","volume":"118","author":"E Ghebremedhin","year":"2009","unstructured":"Ghebremedhin E, Del Tredici K, Langston JW, Braak H (2009) Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson\u2019s disease: an anatomical study. Acta Neuropathol 118:777\u2013784. https:\/\/doi.org\/10.1007\/s00401-009-0596-y","journal-title":"Acta Neuropathol"},{"key":"11267_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/NEN.0b013e3182805c72","volume":"72","author":"TG Beach","year":"2013","unstructured":"Beach TG, Adler CH, Dugger BN et al (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72:130\u2013136. https:\/\/doi.org\/10.1097\/NEN.0b013e3182805c72","journal-title":"J Neuropathol Exp Neurol"},{"key":"11267_CR65","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mds.23344","volume":"26","author":"MG Cersosimo","year":"2011","unstructured":"Cersosimo MG, Perandones C, Micheli FE et al (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson\u2019s disease patients. Mov Disord 26:188\u2013190. https:\/\/doi.org\/10.1002\/mds.23344","journal-title":"Mov Disord"},{"key":"11267_CR66","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00401-010-0665-2","volume":"119","author":"K Del Tredici","year":"2010","unstructured":"Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson\u2019s disease. Acta Neuropathol 119:703\u2013713. https:\/\/doi.org\/10.1007\/s00401-010-0665-2","journal-title":"Acta Neuropathol"},{"key":"11267_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/NEN.0b013e3182965886","volume":"72","author":"L Mu","year":"2013","unstructured":"Mu L, Sobotka S, Chen J et al (2013) Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 72:614\u2013623. https:\/\/doi.org\/10.1097\/NEN.0b013e3182965886","journal-title":"J Neuropathol Exp Neurol"},{"key":"11267_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","volume":"480","author":"M Shi","year":"2010","unstructured":"Shi M, Zabetian CP, Hancock AM et al (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson\u2019s disease. Neurosci Lett 480:78\u201382. https:\/\/doi.org\/10.1016\/j.neulet.2010.06.009","journal-title":"Neurosci Lett"},{"key":"11267_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong Z, Shi M, Chung KA et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease. Brain 133:713\u2013726. https:\/\/doi.org\/10.1093\/brain\/awq008","journal-title":"Brain"},{"key":"11267_CR70","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E et al (2014) Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord 29:1019\u20131027. https:\/\/doi.org\/10.1002\/mds.25772","journal-title":"Mov Disord"},{"key":"11267_CR71","doi-asserted-by":"publisher","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang Y, Shi M, Chung KA et al (2012) Phosphorylated alpha-synuclein in Parkinson\u2019s disease. Sci Transl Med 4:121ra20. https:\/\/doi.org\/10.1126\/scitranslmed.3002566","journal-title":"Sci Transl Med"},{"key":"11267_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0304-3940(98)00599-0","volume":"253","author":"MW Jakowec","year":"1998","unstructured":"Jakowec MW, Petzinger GM, Sastry S et al (1998) The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson\u2019s disease or normal controls. Neurosci Lett 253:13\u201316","journal-title":"Neurosci Lett"},{"key":"11267_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","volume":"7","author":"MJ Park","year":"2011","unstructured":"Park MJ, Cheon SM, Bae HR et al (2011) Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson\u2019s disease. J Clin Neurol 7:215\u2013222. https:\/\/doi.org\/10.3988\/jcn.2011.7.4.215","journal-title":"J Clin Neurol"},{"key":"11267_CR74","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766\u20131772. https:\/\/doi.org\/10.1212\/WNL.0b013e3181fd613b","journal-title":"Neurology"},{"key":"11267_CR75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","volume":"3","author":"T Stewart","year":"2015","unstructured":"Stewart T, Sossi V, Aasly JO et al (2015) Phosphorylated alpha-synuclein in Parkinson\u2019s disease: correlation depends on disease severity. Acta Neuropathol Commun 3:7. https:\/\/doi.org\/10.1186\/s40478-015-0185-3","journal-title":"Acta Neuropathol Commun"},{"key":"11267_CR76","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.22311","volume":"69","author":"M Shi","year":"2011","unstructured":"Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570\u2013580. https:\/\/doi.org\/10.1002\/ana.22311","journal-title":"Ann Neurol"},{"key":"11267_CR77","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Korff A, Shaw LM et al (2013) CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer\u2019s disease. Acta Neuropathol 126:683\u2013697. https:\/\/doi.org\/10.1007\/s00401-013-1148-z","journal-title":"Acta Neuropathol"},{"key":"11267_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052285","volume":"7","author":"LM Smith","year":"2012","unstructured":"Smith LM, Schiess MC, Coffey MP et al (2012) alpha-Synuclein and anti-alpha-synuclein antibodies in Parkinson\u2019s disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS ONE 7:e52285. https:\/\/doi.org\/10.1371\/journal.pone.0052285","journal-title":"PLoS ONE"},{"key":"11267_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","volume":"80","author":"D Besong-Agbo","year":"2013","unstructured":"Besong-Agbo D, Wolf E, Jessen F et al (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169\u2013175. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b90d1","journal-title":"Neurology"},{"key":"11267_CR80","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.22928","volume":"25","author":"R Duran","year":"2010","unstructured":"Duran R, Barrero FJ, Morales B et al (2010) Plasma alpha-synuclein in patients with Parkinson\u2019s disease with and without treatment. Mov Disord 25:489\u2013493. https:\/\/doi.org\/10.1002\/mds.22928","journal-title":"Mov Disord"},{"key":"11267_CR81","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1096\/fj.10-179192","volume":"25","author":"PG Foulds","year":"2011","unstructured":"Foulds PG, Mitchell JD, Parker A et al (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson\u2019s disease. FASEB J 25:4127\u20134137. https:\/\/doi.org\/10.1096\/fj.10-179192","journal-title":"FASEB J"},{"key":"11267_CR82","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","volume":"204","author":"QX Li","year":"2007","unstructured":"Li QX, Mok SS, Laughton KM et al (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson\u2019s disease. Exp Neurol 204:583\u2013588. https:\/\/doi.org\/10.1016\/j.expneurol.2006.12.006","journal-title":"Exp Neurol"},{"key":"11267_CR83","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/archneurol.2010.279","volume":"67","author":"IF Mata","year":"2010","unstructured":"Mata IF, Shi M, Agarwal P et al (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67:1350\u20131356. https:\/\/doi.org\/10.1001\/archneurol.2010.279","journal-title":"Arch Neurol"},{"key":"11267_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052312","volume":"7","author":"A Gorostidi","year":"2012","unstructured":"Gorostidi A, Bergareche A, Ruiz-Martinez J et al (2012) Alphalpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS ONE 7:e52312. https:\/\/doi.org\/10.1371\/journal.pone.0052312","journal-title":"PLoS ONE"},{"key":"11267_CR85","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","volume":"128","author":"M Shi","year":"2014","unstructured":"Shi M, Liu C, Cook TJ et al (2014) Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease. Acta Neuropathol 128:639\u2013650. https:\/\/doi.org\/10.1007\/s00401-014-1314-y","journal-title":"Acta Neuropathol"},{"key":"11267_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018513","volume":"6","author":"K Yanamandra","year":"2011","unstructured":"Yanamandra K, Gruden MA, Casaite V et al (2011) alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson\u2019s disease patients. PLoS ONE 6:e18513. https:\/\/doi.org\/10.1371\/journal.pone.0018513","journal-title":"PLoS ONE"},{"key":"11267_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP et al (2008) Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. Neurodegener Dis 5:55\u201359. https:\/\/doi.org\/10.1159\/000112832","journal-title":"Neurodegener Dis"},{"key":"11267_CR88","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1038\/srep11120","volume":"5","author":"S Abd-Elhadi","year":"2015","unstructured":"Abd-Elhadi S, Honig A, Simhi-Haham D et al (2015) Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson\u2019s Disease. Sci Rep 5:11120. https:\/\/doi.org\/10.1038\/srep11120","journal-title":"Sci Rep"},{"key":"11267_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr015","volume":"134","author":"I Devic","year":"2011","unstructured":"Devic I, Hwang H, Edgar JS et al (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease. Brain 134:e178. https:\/\/doi.org\/10.1093\/brain\/awr015","journal-title":"Brain"},{"key":"11267_CR90","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.neurobiolaging.2013.08.008","volume":"35","author":"T Stewart","year":"2014","unstructured":"Stewart T, Sui Y-T, Gonzalez-Cuyar LF et al (2014) Cheek cell\u2013derived \u03b1-synuclein and DJ-1 do not differentiate Parkinson\u2019s disease from control. Neurobiol Aging 35:418\u2013420. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.08.008","journal-title":"Neurobiol Aging"},{"key":"11267_CR91","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4103\/1947-2714.147980","volume":"6","author":"MS Al-Nimer","year":"2014","unstructured":"Al-Nimer MS, Mshatat SF, Abdulla HI (2014) Saliva alpha-synuclein and a high extinction coefficient protein: a novel approach in assessment biomarkers of Parkinson\u2019s disease. N Am J Med Sci 6:633\u2013637. https:\/\/doi.org\/10.4103\/1947-2714.147980","journal-title":"N Am J Med Sci"},{"key":"11267_CR92","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3978\/j.issn.2223-4292.2015.03.16","volume":"5","author":"FM Lu","year":"2015","unstructured":"Lu FM, Yuan Z (2015) PET\/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg 5:433\u2013447. https:\/\/doi.org\/10.3978\/j.issn.2223-4292.2015.03.16","journal-title":"Quant Imaging Med Surg"},{"key":"11267_CR93","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1101\/gad.1047403","volume":"17","author":"TF Massoud","year":"2003","unstructured":"Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545\u2013580. https:\/\/doi.org\/10.1101\/gad.1047403","journal-title":"Genes Dev"},{"key":"11267_CR94","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1148\/radiology.219.2.r01ma19316","volume":"219","author":"R Weissleder","year":"2001","unstructured":"Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219:316\u2013333. https:\/\/doi.org\/10.1148\/radiology.219.2.r01ma19316","journal-title":"Radiology"},{"key":"11267_CR95","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2174\/156802610791384225","volume":"10","author":"K Chen","year":"2010","unstructured":"Chen K, Chen X (2010) Design and development of molecular imaging probes. Curr Top Med Chem 10:1227\u20131236","journal-title":"Curr Top Med Chem"},{"key":"11267_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.31887\/DCNS.2013.15.3\/ekim","volume":"15","author":"E Kim","year":"2013","unstructured":"Kim E, Howes OD, Kapur S (2013) Molecular imaging as a guide for the treatment of central nervous system disorders. Dialog Clin Neurosci 15:315\u2013328","journal-title":"Dialog Clin Neurosci"},{"key":"11267_CR97","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","volume":"97","author":"ME Phelps","year":"2000","unstructured":"Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97:9226\u20139233. https:\/\/doi.org\/10.1073\/pnas.97.16.9226","journal-title":"Proc Natl Acad Sci USA"},{"key":"11267_CR98","first-page":"139","volume":"45","author":"C Halldin","year":"2001","unstructured":"Halldin C, Gulyas B, Langer O, Farde L (2001) Brain radioligands\u2013state of the art and new trends. Q J Nucl Med 45:139\u2013152","journal-title":"Q J Nucl Med"},{"key":"11267_CR99","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0895-6111(00)00056-2","volume":"25","author":"K Strijckmans","year":"2001","unstructured":"Strijckmans K (2001) The isochronous cyclotron: principles and recent developments. Comput Med Imaging Graph 25:69\u201378","journal-title":"Comput Med Imaging Graph"},{"key":"11267_CR100","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24\u201335","journal-title":"Am J Geriatr Psychiatry"},{"key":"11267_CR101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ana.410280412","volume":"28","author":"DJ Brooks","year":"1990","unstructured":"Brooks DJ, Ibanez V, Sawle GV et al (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28:547\u2013555. https:\/\/doi.org\/10.1002\/ana.410280412","journal-title":"Ann Neurol"},{"key":"11267_CR102","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2466\/15.17.23.PMS.111.5.485-495","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol 55:306\u2013319. https:\/\/doi.org\/10.2466\/15.17.23.PMS.111.5.485-495","journal-title":"Ann Neurol"},{"key":"11267_CR103","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446\u2013452. https:\/\/doi.org\/10.1212\/01.wnl.0000228230.26044.a4","journal-title":"Neurology"},{"key":"11267_CR104","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/archpsyc.1990.01810150013003","volume":"47","author":"L Farde","year":"1990","unstructured":"Farde L, Wiesel FA, Stone-Elander S et al (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213\u2013219","journal-title":"Arch Gen Psychiatry"},{"key":"11267_CR105","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-008-1088-9","volume":"197","author":"J Hirvonen","year":"2008","unstructured":"Hirvonen J, Karlsson H, Kajander J et al (2008) Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology 197:581\u2013590. https:\/\/doi.org\/10.1007\/s00213-008-1088-9","journal-title":"Psychopharmacology"},{"issue":"Pt 1","key":"11267_CR106","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/brain\/123.11.2321","volume":"123","author":"RB Banati","year":"2000","unstructured":"Banati RB, Newcombe J, Gunn RN et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt 1):2321\u20132337","journal-title":"Brain"},{"key":"11267_CR107","first-page":"2207","volume":"36","author":"GN Groom","year":"1995","unstructured":"Groom GN, Junck L, Foster NL et al (1995) PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer\u2019s disease. J Nucl Med 36:2207\u20132210","journal-title":"J Nucl Med"},{"key":"11267_CR108","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/j.1528-1157.1995.tb01066.x","volume":"36","author":"I Savic","year":"1995","unstructured":"Savic I, Thorell JO, Roland P (1995) [11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 36:1225\u20131232","journal-title":"Epilepsia"},{"key":"11267_CR109","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00213-006-0447-7","volume":"188","author":"A Kadir","year":"2006","unstructured":"Kadir A, Almkvist O, Wall A et al (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer\u2019s disease. Psychopharmacology 188:509\u2013520. https:\/\/doi.org\/10.1007\/s00213-006-0447-7","journal-title":"Psychopharmacology"},{"key":"11267_CR110","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1016\/j.bmc.2017.10.010","volume":"25","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ariyoshi T, Ozaki A et al (2017) Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging \u03b1-synuclein aggregates. Bioorg Med Chem 25:6398\u20136403. https:\/\/doi.org\/10.1016\/j.bmc.2017.10.010","journal-title":"Bioorg Med Chem"},{"key":"11267_CR111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40336-016-0217-4","volume":"5","author":"PT Kotzbauer","year":"2017","unstructured":"Kotzbauer PT, Tu Z, Mach RH (2017) Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. Clin Transl Imaging 5:3\u201314. https:\/\/doi.org\/10.1007\/s40336-016-0217-4","journal-title":"Clin Transl Imaging"},{"key":"11267_CR112","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1471-4159.2008.05245.x","volume":"105","author":"L Ye","year":"2008","unstructured":"Ye L, Velasco A, Fraser G et al (2008) In vitro high affinity \u03b1-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105:1428\u20131437. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05245.x","journal-title":"J Neurochem"},{"key":"11267_CR113","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","volume":"27","author":"MT Fodero-Tavoletti","year":"2007","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA et al (2007) In vitro characterization of Pittsburgh compound-B binding to lewy bodies. J Neurosci 27:10365\u201310371. https:\/\/doi.org\/10.1523\/JNEUROSCI.0630-07.2007","journal-title":"J Neurosci"},{"key":"11267_CR114","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","volume":"617","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Mulligan RS, Okamura N et al (2009) In vitro characterisation of BF227 binding to \u03b1-synuclein\/Lewy bodies. Eur J Pharmacol 617:54\u201358. https:\/\/doi.org\/10.1016\/j.ejphar.2009.06.042","journal-title":"Eur J Pharmacol"},{"key":"11267_CR115","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","volume":"20","author":"L Yu","year":"2012","unstructured":"Yu L, Cui J, Padakanti PK et al (2012) Synthesis and in vitro evaluation of \u03b1-synuclein ligands. Bioorg Med Chem 20:4625\u20134634. https:\/\/doi.org\/10.1016\/j.bmc.2012.06.023","journal-title":"Bioorg Med Chem"},{"key":"11267_CR116","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/app4010066","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang X, Jin H, Padakanti PK et al (2014) Radiosynthesis and in vivo evaluation of two PET radioligands for imaging \u03b1-synuclein. Appl Sci (Switz) 4:66\u201378. https:\/\/doi.org\/10.3390\/app4010066","journal-title":"Appl Sci (Switz)"},{"key":"11267_CR117","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","volume":"58","author":"W Chu","year":"2015","unstructured":"Chu W, Zhou D, Gaba V et al (2015) Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for \u03b1-synuclein fibrils. J Med Chem 58:6002\u20136017. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00571","journal-title":"J Med Chem"},{"key":"11267_CR118","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41401-019-0304-y","volume":"41","author":"M Xuming","year":"2020","unstructured":"Xuming M, Ryan P, Rudrawar S et al (2020) Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. Acta Pharmacol Sin 41:483\u2013498. https:\/\/doi.org\/10.1038\/s41401-019-0304-y","journal-title":"Acta Pharmacol Sin"},{"key":"11267_CR119","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.bbadis.2008.10.003","volume":"1792","author":"N Pavese","year":"2009","unstructured":"Pavese N, Brooks DJ (2009) Imaging neurodegeneration in Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis 1792:722\u2013729. https:\/\/doi.org\/10.1016\/j.bbadis.2008.10.003","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"11267_CR120","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/412486","volume":"2012","author":"L Wang","year":"2012","unstructured":"Wang L, Zhang Q, Li H, Zhang H (2012) SPECT molecular imaging in Parkinson\u2019s disease. J Biomed Biotechnol 2012:412486. https:\/\/doi.org\/10.1155\/2012\/412486","journal-title":"J Biomed Biotechnol"},{"key":"11267_CR121","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1046\/j.1471-4159.2002.00928.x","volume":"81","author":"HM Gao","year":"2002","unstructured":"Gao HM, Jiang J, Wilson B et al (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson\u2019s disease. J Neurochem 81:1285\u20131297","journal-title":"J Neurochem"},{"key":"11267_CR122","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0306-4522(99)00455-8","volume":"95","author":"B Mirza","year":"2000","unstructured":"Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson\u2019s disease. Neuroscience 95:425\u2013432","journal-title":"Neuroscience"},{"key":"11267_CR123","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-3940(03)00172-1","volume":"341","author":"TB Sherer","year":"2003","unstructured":"Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson\u2019s disease. Neurosci Lett 341:87\u201390","journal-title":"Neurosci Lett"},{"key":"11267_CR124","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0006-8993(02)04085-4","volume":"964","author":"S Sugama","year":"2003","unstructured":"Sugama S, Yang L, Cho BP et al (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL\/6 mice. Brain Res 964:288\u2013294","journal-title":"Brain Res"},{"key":"11267_CR125","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00019052-200108000-00009","volume":"14","author":"M Vila","year":"2001","unstructured":"Vila M, Jackson-Lewis V, Guegan C et al (2001) The role of glial cells in Parkinson\u2019s disease. Curr Opin Neurol 14:483\u2013489","journal-title":"Curr Opin Neurol"},{"key":"11267_CR126","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","volume":"19","author":"GW Kreutzberg","year":"1996","unstructured":"Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312\u2013318","journal-title":"Trends Neurosci"},{"key":"11267_CR127","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.20338","volume":"57","author":"Y Ouchi","year":"2005","unstructured":"Ouchi Y, Yoshikawa E, Sekine Y et al (2005) Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol 57:168\u2013175. https:\/\/doi.org\/10.1002\/ana.20338","journal-title":"Ann Neurol"},{"key":"11267_CR128","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis 21:404\u2013412. https:\/\/doi.org\/10.1016\/j.nbd.2005.08.002","journal-title":"Neurobiol Dis"},{"key":"11267_CR129","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/7854_2011_165","volume":"11","author":"P Cumming","year":"2012","unstructured":"Cumming P, Borghammer P (2012) Molecular imaging and the neuropathologies of Parkinson\u2019s disease. Curr Top Behav Neurosci 11:117\u2013148. https:\/\/doi.org\/10.1007\/7854_2011_165","journal-title":"Curr Top Behav Neurosci"},{"key":"11267_CR130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/NDT.S32302","volume":"9","author":"DJ Pedrosa","year":"2013","unstructured":"Pedrosa DJ, Timmermann L (2013) Review: management of Parkinson\u2019s disease. Neuropsychiatr Dis Treat 9:321\u2013340. https:\/\/doi.org\/10.2147\/NDT.S32302","journal-title":"Neuropsychiatr Dis Treat"},{"key":"11267_CR131","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0896-6273(03)00201-0","volume":"38","author":"MB Feany","year":"2003","unstructured":"Feany MB, Pallanck LJ (2003) Parkin: a multipurpose neuroprotective agent? Neuron 38:13\u201316","journal-title":"Neuron"},{"key":"11267_CR132","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A (2012) Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2:a008888. https:\/\/doi.org\/10.1101\/cshperspect.a008888","journal-title":"Cold Spring Harb Perspect Med"},{"key":"11267_CR133","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm3028","volume":"12","author":"RJ Youle","year":"2011","unstructured":"Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12:9\u201314. https:\/\/doi.org\/10.1038\/nrm3028","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11267_CR134","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1021\/acschemneuro.5b00172","volume":"6","author":"J Kakish","year":"2015","unstructured":"Kakish J, Lee D, Lee JS (2015) Drugs that bind to alpha-synuclein: neuroprotective or neurotoxic? ACS Chem Neurosci 6:1930\u20131940. https:\/\/doi.org\/10.1021\/acschemneuro.5b00172","journal-title":"ACS Chem Neurosci"},{"key":"11267_CR135","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","volume":"355","author":"O Bar Am","year":"2004","unstructured":"Bar Am O, Amit T, Youdim MB (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169\u2013172","journal-title":"Neurosci Lett"},{"key":"11267_CR136","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1471-4159.2009.06542.x","volume":"112","author":"O Bar-Am","year":"2010","unstructured":"Bar-Am O, Weinreb O, Amit T, Youdim MB (2010) The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 112:1131\u20131137. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06542.x","journal-title":"J Neurochem"},{"key":"11267_CR137","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.neuint.2010.06.017","volume":"57","author":"KY Chau","year":"2010","unstructured":"Chau KY, Cooper JM, Schapira AH (2010) Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int 57:525\u2013529. https:\/\/doi.org\/10.1016\/j.neuint.2010.06.017","journal-title":"Neurochem Int"},{"key":"11267_CR138","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2210-11-2","volume":"11","author":"W Dimpfel","year":"2011","unstructured":"Dimpfel W, Hoffmann JA (2011) Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 11:2. https:\/\/doi.org\/10.1186\/1471-2210-11-2","journal-title":"BMC Pharmacol"},{"key":"11267_CR139","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","volume":"277","author":"SP Patil","year":"2014","unstructured":"Patil SP, Jain PD, Ghumatkar PJ et al (2014) Neuroprotective effect of metformin in MPTP-induced Parkinson\u2019s disease in mice. Neuroscience 277:747\u2013754. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.07.046","journal-title":"Neuroscience"},{"key":"11267_CR140","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","volume":"79","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Munhoz RP et al (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79:651\u2013658. https:\/\/doi.org\/10.1212\/WNL.0b013e318263570d","journal-title":"Neurology"},{"key":"11267_CR141","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-091459","author":"RDS Prediger","year":"2010","unstructured":"Prediger RDS (2010) Effects of caffeine in Parkinson\u2019s disease: From neuroprotection to the management of motor and non-motor symptoms. J Alzheimer Dis. https:\/\/doi.org\/10.3233\/JAD-2010-091459","journal-title":"J Alzheimer Dis"},{"key":"11267_CR142","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tins.2004.06.008","volume":"27","author":"M Quik","year":"2004","unstructured":"Quik M (2004) Smoking, nicotine and Parkinson\u2019s disease. Trends Neurosci 27:561\u2013568. https:\/\/doi.org\/10.1016\/j.tins.2004.06.008","journal-title":"Trends Neurosci"},{"key":"11267_CR143","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mds.25028","volume":"27","author":"M Quik","year":"2012","unstructured":"Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson\u2019s disease. Mov Disord 27:947\u2013957. https:\/\/doi.org\/10.1002\/mds.25028","journal-title":"Mov Disord"},{"key":"11267_CR144","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2165\/00002512-200118110-00001","volume":"18","author":"GW Ross","year":"2001","unstructured":"Ross GW, Petrovitch H (2001) Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson\u2019s disease. Drugs Aging 18:797\u2013806. https:\/\/doi.org\/10.2165\/00002512-200118110-00001","journal-title":"Drugs Aging"},{"key":"11267_CR145","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","volume":"18","author":"ML Wahlqvist","year":"2012","unstructured":"Wahlqvist ML, Lee MS, Hsu CC et al (2012) Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson\u2019s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinson Relat Disord 18:753\u2013758. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.03.010","journal-title":"Parkinson Relat Disord"},{"key":"11267_CR146","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"D Games","year":"2014","unstructured":"Games D, Valera E, Spencer B et al (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J Neurosci 34:9441\u20139454. https:\/\/doi.org\/10.1523\/JNEUROSCI.5314-13.2014","journal-title":"J Neurosci"},{"key":"11267_CR147","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","volume":"170","author":"BM Dufty","year":"2007","unstructured":"Dufty BM, Warner LR, Hou ST et al (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170:1725\u20131738. https:\/\/doi.org\/10.2353\/ajpath.2007.061232","journal-title":"Am J Pathol"},{"key":"11267_CR148","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/rcm.8540","volume":"33","author":"CK Nwabufo","year":"2019","unstructured":"Nwabufo CK, El-Aneed A, Krol ES (2019) Tandem mass spectrometric analysis of novel caffeine scaffold-based bifunctional compounds for Parkinson\u2019s disease. Rapid Commun Mass Spectrom 33:1792\u20131803. https:\/\/doi.org\/10.1002\/rcm.8540","journal-title":"Rapid Commun Mass Spectrom"},{"key":"11267_CR149","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/00498254.2021.1943566","volume":"51","author":"CK Nwabufo","year":"2021","unstructured":"Nwabufo CK, Aigbogun OP, Allen KJH et al (2021) Employing in vitro metabolism to guide design of F-labelled PET probes of novel \u03b1-synuclein binding bifunctional compounds. Xenobiotica 51:885\u2013900. https:\/\/doi.org\/10.1080\/00498254.2021.1943566","journal-title":"Xenobiotica"},{"key":"11267_CR150","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.dmpk.2018.09.208","volume":"34","author":"C Nwabufo","year":"2019","unstructured":"Nwabufo C, Krol E (2019) Unraveling the metabolic fate of potential therapeutic dimer compounds for Parkinson\u2019s disease. Drug Metab Pharmacokinet 34:S59\u2013S60","journal-title":"Drug Metab Pharmacokinet"},{"key":"11267_CR151","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"G Hussain","year":"2018","unstructured":"Hussain G, Rasul A, Anwar H et al (2018) Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int J Biol Sci 14:341\u2013357. https:\/\/doi.org\/10.7150\/ijbs.23247","journal-title":"Int J Biol Sci"},{"key":"11267_CR152","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejmech.2017.09.068","volume":"141","author":"H Zhang","year":"2017","unstructured":"Zhang H, Bai L, He J et al (2017) Recent advances in discovery and development of natural products as source for anti-Parkinson\u2019s disease lead compounds. Eur J Med Chem 141:257\u2013272. https:\/\/doi.org\/10.1016\/j.ejmech.2017.09.068","journal-title":"Eur J Med Chem"},{"key":"11267_CR153","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neuropharm.2013.08.007","volume":"82","author":"RH Fu","year":"2014","unstructured":"Fu RH, Wang YC, Chen CS et al (2014) Acetylcorynoline attenuates dopaminergic neuron degeneration and \u03b1-synuclein aggregation in animal models of Parkinson\u2019s disease. Neuropharmacology 82:108\u2013120. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.007","journal-title":"Neuropharmacology"},{"key":"11267_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110576","volume":"130","author":"YH Leem","year":"2020","unstructured":"Leem YH, Park JS, Park JE et al (2020) Papaverine inhibits \u03b1-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP\/P mouse model of Parkinson\u2019s disease. Biomed Pharmacother 130:110576. https:\/\/doi.org\/10.1016\/j.biopha.2020.110576","journal-title":"Biomed Pharmacother"},{"key":"11267_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26154627","author":"RL Jayaraj","year":"2021","unstructured":"Jayaraj RL, Beiram R, Azimullah S et al (2021) Noscapine prevents rotenone-induced neurotoxicity: Involvement of oxidative stress, neuroinflammation and autophagy pathways. Molecules. https:\/\/doi.org\/10.3390\/molecules26154627","journal-title":"Molecules"},{"key":"11267_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26123736","volume":"26","author":"SS Ghanem","year":"2021","unstructured":"Ghanem SS, Fayed HS, Zhu Q et al (2021) Natural alkaloid compounds as inhibitors for alpha-synuclein seeded fibril formation and toxicity. Molecules 26:1\u201313. https:\/\/doi.org\/10.3390\/molecules26123736","journal-title":"Molecules"},{"key":"11267_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100788","volume":"296","author":"CB Andersen","year":"2021","unstructured":"Andersen CB, Yoshimura Y, Nielsen J et al (2021) How epigallocatechin gallate binds and assembles oligomeric forms of human alpha-synuclein. J Biol Chem 296:100788. https:\/\/doi.org\/10.1016\/j.jbc.2021.100788","journal-title":"J Biol Chem"},{"key":"11267_CR158","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1021\/acschemneuro.0c00598","volume":"11","author":"Y Yao","year":"2020","unstructured":"Yao Y, Tang Y, Wei G (2020) Epigallocatechin gallate destabilizes \u03b1-synuclein fibril by disrupting the E46\u2013K80 salt-bridge and inter-protofibril interface. ACS Chem Neurosci 11:4351\u20134361. https:\/\/doi.org\/10.1021\/acschemneuro.0c00598","journal-title":"ACS Chem Neurosci"},{"key":"11267_CR159","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","volume":"286","author":"M Chen","year":"2015","unstructured":"Chen M, Wang T, Yue F et al (2015) Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral \u03b1-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience 286:383\u2013392. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.12.003","journal-title":"Neuroscience"},{"key":"11267_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18349-z","volume":"7","author":"JE Yang","year":"2017","unstructured":"Yang JE, Rhoo KY, Lee S et al (2017) EGCG-mediated protection of the membrane disruption and cytotoxicity caused by the \u201cactive oligomer\u201d of \u03b1-synuclein. Sci Rep 7:1\u201310. https:\/\/doi.org\/10.1038\/s41598-017-18349-z","journal-title":"Sci Rep"},{"key":"11267_CR161","doi-asserted-by":"publisher","first-page":"26846","DOI":"10.1074\/jbc.M403129200","volume":"279","author":"M Zhu","year":"2004","unstructured":"Zhu M, Rajamani S, Kaylor J et al (2004) The flavonoid baicalein inhibits fibrillation of \u03b1-synuclein and disaggregates existing fibrils. J Biol Chem 279:26846\u201326857. https:\/\/doi.org\/10.1074\/jbc.M403129200","journal-title":"J Biol Chem"},{"key":"11267_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-39480-z","volume":"9","author":"MJ Daniels","year":"2019","unstructured":"Daniels MJ, Nourse JB, Kim H et al (2019) Cyclized NDGA modifies dynamic \u03b1-synuclein monomers preventing aggregation and toxicity. Sci Rep 9:1\u201317. https:\/\/doi.org\/10.1038\/s41598-019-39480-z","journal-title":"Sci Rep"},{"key":"11267_CR163","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.molmed.2020.01.005","volume":"26","author":"J Pujols","year":"2020","unstructured":"Pujols J, Pe\u00f1a-D\u00edaz S, Pallar\u00e8s I, Ventura S (2020) Chemical chaperones as novel drugs for Parkinson\u2019s disease. Trends Mol Med 26:408\u2013421. https:\/\/doi.org\/10.1016\/j.molmed.2020.01.005","journal-title":"Trends Mol Med"},{"key":"11267_CR164","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/sj.emboj.7600211","volume":"23","author":"CO Fern\u00e1ndez","year":"2004","unstructured":"Fern\u00e1ndez CO, Hoyer W, Zweckstetter M et al (2004) NMR of \u03b1-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23:2039\u20132046. https:\/\/doi.org\/10.1038\/sj.emboj.7600211","journal-title":"EMBO J"},{"key":"11267_CR165","doi-asserted-by":"publisher","first-page":"E2543","DOI":"10.1073\/pnas.1701964114","volume":"114","author":"M Perni","year":"2017","unstructured":"Perni M, Galvagnion C, Maltsev A, Meisl G, M\u00fcller MBD, Challa PK, Kirkegaard JB, Flagmeier P, Cohen SIA, Cascella R, Chen SW, Limbocker R, Sormanni P, Heller GT, Fra CMD (2017) A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA 114:E2543. https:\/\/doi.org\/10.1073\/pnas.1701964114","journal-title":"Proc Natl Acad Sci USA"},{"key":"11267_CR166","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","volume":"13","author":"M Perni","year":"2018","unstructured":"Perni M, Flagmeier P, Limbocker R et al (2018) Multistep Inhibition of \u03b1-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol 13:2308\u20132319. https:\/\/doi.org\/10.1021\/acschembio.8b00466","journal-title":"ACS Chem Biol"},{"key":"11267_CR167","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li J, Zhu M, Rajamani S et al (2004) Rifampicin inhibits-synuclein fibrillation and disaggregates fibrils. Chem Biol 11:1513\u20131521","journal-title":"Chem Biol"},{"key":"11267_CR168","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.brainres.2006.12.074","volume":"1139","author":"J Xu","year":"2007","unstructured":"Xu J, Wei C, Xu C et al (2007) Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an \u03b1-Synuclein multimer. Brain Res 1139:220\u2013225. https:\/\/doi.org\/10.1016\/j.brainres.2006.12.074","journal-title":"Brain Res"},{"key":"11267_CR169","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","volume":"13","author":"PA Low","year":"2014","unstructured":"Low PA, Robertson D, Gilman S et al (2014) Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:268\u2013275. https:\/\/doi.org\/10.1016\/S1474-4422(13)70301-6","journal-title":"Lancet Neurol"},{"key":"11267_CR170","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/13543784.2016.1237501","volume":"25","author":"N T\u00f6r\u00f6k","year":"2016","unstructured":"T\u00f6r\u00f6k N, Majl\u00e1th Z, Szal\u00e1rdy L, V\u00e9csei L (2016) Investigational \u03b1-synuclein aggregation inhibitors: hope for Parkinson\u2019s disease. Expert Opin Investig Drugs 25:1281\u20131294. https:\/\/doi.org\/10.1080\/13543784.2016.1237501","journal-title":"Expert Opin Investig Drugs"},{"key":"11267_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105256","author":"A Dominguez-Meijide","year":"2021","unstructured":"Dominguez-Meijide A, Parrales V, Vasili E et al (2021) Doxycycline inhibits \u03b1-synuclein-associated pathologies in vitro and in vivo. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2021.105256","journal-title":"Neurobiol Dis"},{"key":"11267_CR172","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbr.2019.02.020","volume":"364","author":"CH Tai","year":"2019","unstructured":"Tai CH, Bellesi M, Chen AC et al (2019) A new avenue for treating neuronal diseases: ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behav Brain Res 364:149\u2013156. https:\/\/doi.org\/10.1016\/j.bbr.2019.02.020","journal-title":"Behav Brain Res"},{"key":"11267_CR173","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/15548627.2016.1179404","volume":"12","author":"JX Song","year":"2016","unstructured":"Song JX, Sun YR, Peluso I et al (2016) A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition. Autophagy 12:1372\u20131389. https:\/\/doi.org\/10.1080\/15548627.2016.1179404","journal-title":"Autophagy"},{"key":"11267_CR174","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1021\/acsnano.9b06453","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Liu C, Zhang J et al (2020) A self-assembled \u03b1-synuclein nanoscavenger for Parkinson\u2019s disease. ACS Nano 14:1533\u20131549. https:\/\/doi.org\/10.1021\/acsnano.9b06453","journal-title":"ACS Nano"},{"key":"11267_CR175","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino V, Di Malta A, Donaudy C, Polishchuk RS, Banfi S, Cattaneo PG, Ballabio EA (2009) A gene network regulating lysosomal biogenesis and function. Science 325:473\u2013478","journal-title":"Science"},{"key":"11267_CR176","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305623110","author":"M Decressac","year":"2013","unstructured":"Decressac M, Mattsson B, Weikop P et al (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.1305623110","journal-title":"Proc Natl Acad Sci USA"},{"key":"11267_CR177","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.neurol.2022.03.010","volume":"178","author":"M Lopez-Cuina","year":"2022","unstructured":"Lopez-Cuina M, Meissner WG (2022) Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders. Revue Neurologique 178:460\u2013471. https:\/\/doi.org\/10.1016\/j.neurol.2022.03.010","journal-title":"Revue Neurologique"},{"key":"11267_CR178","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","volume":"7","author":"HT Tran","year":"2014","unstructured":"Tran HT, Chung CH-Y, Iba M et al (2014) \u03b1-Synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration. Cell Rep 7:2054\u20132065. https:\/\/doi.org\/10.1016\/j.celrep.2014.05.033","journal-title":"Cell Rep"},{"key":"11267_CR179","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","volume":"46","author":"E Masliah","year":"2005","unstructured":"Masliah E, Rockenstein E, Adame A et al (2005) Effects of \u03b1-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron 46:857\u2013868. https:\/\/doi.org\/10.1016\/j.neuron.2005.05.010","journal-title":"Neuron"},{"key":"11267_CR180","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","volume":"5","author":"B Spencer","year":"2017","unstructured":"Spencer B, Valera E, Rockenstein E et al (2017) Anti-\u03b1-synuclein immunotherapy reduces \u03b1-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun 5:7. https:\/\/doi.org\/10.1186\/s40478-016-0410-8","journal-title":"Acta Neuropathol Commun"},{"key":"11267_CR181","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","volume":"5","author":"E Valera","year":"2017","unstructured":"Valera E, Spencer B, Fields JA et al (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5:2. https:\/\/doi.org\/10.1186\/s40478-016-0409-1","journal-title":"Acta Neuropathol Commun"},{"key":"11267_CR182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy Body disease. PLoS ONE 6:e19338. https:\/\/doi.org\/10.1371\/journal.pone.0019338","journal-title":"PLoS ONE"},{"key":"11267_CR183","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","volume":"10","author":"M Mandler","year":"2015","unstructured":"Mandler M, Valera E, Rockenstein E et al (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegeneration 10:10. https:\/\/doi.org\/10.1186\/s13024-015-0008-9","journal-title":"Mol Neurodegeneration"},{"key":"11267_CR184","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","volume":"127","author":"M Mandler","year":"2014","unstructured":"Mandler M, Valera E, Rockenstein E et al (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s disease clinical trials. Acta Neuropathol 127:861\u2013879. https:\/\/doi.org\/10.1007\/s00401-014-1256-4","journal-title":"Acta Neuropathol"},{"key":"11267_CR185","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","volume":"182","author":"D Games","year":"2013","unstructured":"Games D, Seubert P, Rockenstein E et al (2013) Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of c-terminal\u2013truncated \u03b1-synuclein. Am J Pathol 182:940\u2013953. https:\/\/doi.org\/10.1016\/j.ajpath.2012.11.018","journal-title":"Am J Pathol"},{"key":"11267_CR186","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.26878","volume":"32","author":"DB Schenk","year":"2017","unstructured":"Schenk DB, Koller M, Ness DK et al (2017) First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers: immunotherapy for Parkinson\u2019s disease. Mov Disord 32:211\u2013218. https:\/\/doi.org\/10.1002\/mds.26878","journal-title":"Mov Disord"},{"key":"11267_CR187","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Goodman I, Safirstein B et al (2018) Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75:1206. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1487","journal-title":"JAMA Neurol"},{"key":"11267_CR188","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","volume":"69","author":"V Lindstr\u00f6m","year":"2014","unstructured":"Lindstr\u00f6m V, Fagerqvist T, Nordstr\u00f6m E et al (2014) Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice. Neurobiol Dis 69:134\u2013143. https:\/\/doi.org\/10.1016\/j.nbd.2014.05.009","journal-title":"Neurobiol Dis"},{"key":"11267_CR189","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fnins.2018.00452","volume":"12","author":"M Kallab","year":"2018","unstructured":"Kallab M, Herrera-Vaquero M, Johannesson M et al (2018) Region-specific effects of immunotherapy with antibodies targeting \u03b1-synuclein in a transgenic model of synucleinopathy. Front Neurosci 12:452. https:\/\/doi.org\/10.3389\/fnins.2018.00452","journal-title":"Front Neurosci"},{"key":"11267_CR190","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","volume":"124","author":"A Weihofen","year":"2019","unstructured":"Weihofen A, Liu Y, Arndt JW et al (2019) Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis 124:276\u2013288. https:\/\/doi.org\/10.1016\/j.nbd.2018.10.016","journal-title":"Neurobiol Dis"},{"key":"11267_CR191","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","volume":"34","author":"M Brys","year":"2019","unstructured":"Brys M, Fanning L, Hung S et al (2019) Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054. Mov Disord 34:1154\u20131163. https:\/\/doi.org\/10.1002\/mds.27738","journal-title":"Mov Disord"},{"key":"11267_CR192","unstructured":"Biogen Annual Report (2020) Biogen"},{"key":"11267_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield DJ, Irving L, Calo L et al (2019) Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo. Neurobiol Dis 132:104582. https:\/\/doi.org\/10.1016\/j.nbd.2019.104582","journal-title":"Neurobiol Dis"},{"key":"11267_CR194","doi-asserted-by":"publisher","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","volume":"13","author":"L Fjord-Larsen","year":"2021","unstructured":"Fjord-Larsen L, Thougaard A, Wegener KM et al (2021) Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs 13:1994690. https:\/\/doi.org\/10.1080\/19420862.2021.1994690","journal-title":"MAbs"},{"key":"11267_CR195","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/03602532.2021.1959606","volume":"53","author":"A Thakur","year":"2021","unstructured":"Thakur A, Tan Z, Kameyama T et al (2021) Bioanalytical strategies in drug discovery and development. Drug Metab Rev 53:434\u2013458. https:\/\/doi.org\/10.1080\/03602532.2021.1959606","journal-title":"Drug Metab Rev"},{"key":"11267_CR196","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/03602532.2021.1909614","volume":"53","author":"CK Nwabufo","year":"2021","unstructured":"Nwabufo CK (2021) Introduction to the mini special issue on next generation drug discovery and development: rethinking translational pharmacology for accelerated drug development. Drug Metab Rev 53:171\u2013172. https:\/\/doi.org\/10.1080\/03602532.2021.1909614","journal-title":"Drug Metab Rev"},{"key":"11267_CR197","doi-asserted-by":"publisher","DOI":"10.2174\/1389200223666220621113524","author":"CK Nwabufo","year":"2022","unstructured":"Nwabufo CK (2022) Relevance of ABC transporters in drug development. CDM. https:\/\/doi.org\/10.2174\/1389200223666220621113524","journal-title":"CDM"},{"key":"11267_CR198","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jpba.2012.03.001","volume":"66","author":"J Hou","year":"2012","unstructured":"Hou J, Qu F, Wu C et al (2012) Quantitative determination and pharmacokinetic study of the novel anti-Parkinson\u2019s disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 66:232\u2013239. https:\/\/doi.org\/10.1016\/j.jpba.2012.03.001","journal-title":"J Pharm Biomed Anal"},{"key":"11267_CR199","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","volume":"115","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Willemsen ATM, Kortekaas R et al (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson\u2019s disease, PSP and MSA. J Neural Transm 115:1001\u20131009. https:\/\/doi.org\/10.1007\/s00702-008-0030-y","journal-title":"J Neural Transm"},{"key":"11267_CR200","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","volume":"57","author":"BV Zlokovic","year":"2008","unstructured":"Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178\u2013201. https:\/\/doi.org\/10.1016\/j.neuron.2008.01.003","journal-title":"Neuron"},{"key":"11267_CR201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102442","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Hou J, Chen X et al (2014) P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson\u2019s disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. PLoS ONE 9:e102442. https:\/\/doi.org\/10.1371\/journal.pone.0102442","journal-title":"PLoS ONE"},{"key":"11267_CR202","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/484963","volume":"2015","author":"FG Hoosain","year":"2015","unstructured":"Hoosain FG, Choonara YE, Tomar LK et al (2015) Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int 2015:484963. https:\/\/doi.org\/10.1155\/2015\/484963","journal-title":"Biomed Res Int"},{"key":"11267_CR203","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1039\/C3CS60430F","volume":"43","author":"L Zhu","year":"2014","unstructured":"Zhu L, Ploessl K, Kung HF (2014) PET\/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev 43:6683\u20136691. https:\/\/doi.org\/10.1039\/C3CS60430F","journal-title":"Chem Soc Rev"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11267-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11267-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11267-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:49:22Z","timestamp":1744188562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11267-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":203,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["11267"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11267-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial relationship to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}